Background and Purpose: Aging spontaneously hypertensive stroke-prone rats (SHR-SP) were previously shown to develop neocortical strokes. Because the hippocampal CA1 is selectively vulnerable to abnormal brain perfusion, the neuropathological effects of spontaneous strokes were investigated on specific neurochemical alterations in two major cell types of the hippocampal CA1 in SHR-SP.Methods: The immunoreactivity for the y-isoform of protein kinase C (in pyramidal cells) and parvalbumin (in interneurons) was determined in the hippocampal CA1 by applying monoclonal antibodies. Because chronic treatment with the calcium antagonist nimodipine prevents the development of strokes in SHR-SP, we compared SHR-SP (stroke) with age-matched nimodipine-treated rats (nonstroke).Results: After stroke in control animals, we observed a strikingly enhanced immunoreactivity for protein kinase C-y in CA1 pyramidal cells compared with nimodipine-treated rats, which can be interpreted as the result of an increased activation of these cells. The pathological increase of protein kinase C-y immunoreactivity was accompanied by a reduced parvalbuminergic innervation of these pyramidal cells in symptomatic SHR-SP.Conclusions: Because parvalbumin is present in a subset of GABAergic inhibitory interneurons, these data suggest that increased activity of CAl pyramidal cells after spontaneous stroke may partially be related to a decreased inhibitory input on these cells. (Stroke. 1993;24:2082-2086 See Editorial Comment, page 2086 glutamate in the hippocampus during cerebral ischemia is a key factor in ischemia-induced neuronal damage and cell death.9 Enhancement of the activity and/or translocation of the enzyme protein kinase C (PKC) might also play an important role in postischemic alteration of neuronal functioning in the hippocampus.10-12 More recently some attention has also been directed to possible alterations in postsynaptic inhibitory processes after ischemia.13Much less is known about neurochemical alterations after spontaneous strokes. We previously showed that chronic application of the calcium entry blocker nimodipine starting at the age of 46 weeks prevented the occurrence of stroke in SHR-SP5,6 without reducing the (high) systolic blood pressure.5 Comparison of agematched SHR-SP with (nontreated) and without (nimodipine-treated) spontaneous strokes enabled us to reveal neurochemical alterations that occur after spontaneous strokes. In the present study we examined the effect of stroke in aging SHR-SP on the expression of PKCy and the calcium binding protein parvalbumin (PV) De Jong et al Stroke, Protein Kinase C-y, and Parvalbumin 2083 mark). At the age of 46 weeks the animals were divided into two groups (both n= 11), one of which received standard food pellets (SP-placebo). The other group (SP-nimo) received identical food pellets to which 860 ppm nimodipine (Bayer AG, Leverkussen, Germany) was added. Treatment was carried out for a period of 10 weeks (from 46 to 56 weeks), after which the experiment had to be terminated bec...